{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:43:10Z","timestamp":1780713790192,"version":"3.54.1"},"publisher-location":"Cham","reference-count":86,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031280115","type":"print"},{"value":"9783031280122","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-3-031-28012-2_18","type":"book-chapter","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T12:02:41Z","timestamp":1687953761000},"page":"339-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients"],"prefix":"10.1007","author":[{"given":"Maryam","family":"Khanahmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danial","family":"Khayatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayyeh","family":"Hashemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Abdolghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"18_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.onehlt.2020.100124","volume":"9","author":"ME El Zowalaty","year":"2020","unstructured":"El Zowalaty ME,J\u00e4rhult JD (2020) From SARS to COVID-19: A previously unknown SARS-related coronavirus (SARS-CoV-2) of pandemic potential infecting humans\u2013Call for a One Health approach. One Health 9:100124. https:\/\/doi.org\/10.1016\/j.onehlt.2020.100124","journal-title":"One Health"},{"issue":"3","key":"18_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"CC Lai","year":"2020","unstructured":"Lai CC, Shih TP, Ko WC, et al (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 55(3):105924. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105924","journal-title":"Int J Antimicrob Agents"},{"issue":"5\u20136","key":"18_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/1073858420941476","volume":"26","author":"D Kempuraj","year":"2020","unstructured":"Kempuraj D, Selvakumar GP, Ahmed ME, et al. (2020) COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist 26(5\u20136):402\u2013414","journal-title":"Neuroscientist"},{"key":"18_CR4","unstructured":"Coronavirus (COVID-19) Vaccinations. https:\/\/ourworldindata.org\/covid-vaccinations. Accessed October 18, 2022"},{"issue":"1","key":"18_CR5","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-022-31441-x","volume":"13","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Wyka K, White TM, et al (2022) Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nat Commun 13(1):3801. https:\/\/doi.org\/10.1038\/s41467-022-31441-x","journal-title":"Nat Commun"},{"issue":"1","key":"18_CR6","first-page":"1","volume":"30","author":"HA Mushtaq","year":"2022","unstructured":"Mushtaq HA, Khedr A, Koritala T, et al (2022) A review of adverse effects of COVID-19 vaccines. Infez Med. 30(1):1\u201310","journal-title":"Infez Med."},{"issue":"1","key":"18_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13337-022-00755-1","volume":"33","author":"MM Rahman","year":"2022","unstructured":"Rahman MM, Masum MHU, Wajed S, Talukder A (2022) A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. Virusdisease 33(1):1\u201322. https:\/\/doi.org\/10.1007\/s13337-022-00755-1","journal-title":"Virusdisease"},{"issue":"1","key":"18_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12929-022-00853-8","volume":"29","author":"WY Chi","year":"2022","unstructured":"Chi WY, Li YD, Huang HC, Chan TEH, et al (2022) COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 29(1):82. https:\/\/doi.org\/10.1186\/s12929-022-00853-8","journal-title":"J Biomed Sci"},{"issue":"1","key":"18_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15177","volume":"35","author":"ML Musumeci","year":"2022","unstructured":"Musumeci ML, Caruso G, Trecarichi AC, Micali G (2022) Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience. Dermatol Ther 35(1):e15177. https:\/\/doi.org\/10.1111\/dth.15177","journal-title":"Dermatol Ther"},{"issue":"5","key":"18_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15408","volume":"35","author":"\u00c9A Piros","year":"2022","unstructured":"Piros \u00c9A, Cseprek\u00e1l O, G\u00f6r\u00f6g A, et al (2022) Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study. Dermatol Ther 35(5):e15408. https:\/\/doi.org\/10.1111\/dth.15408","journal-title":"Dermatol Ther"},{"issue":"6","key":"18_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15461","volume":"35","author":"F Seirafianpour","year":"2022","unstructured":"Seirafianpour F, Pourriyahi H, Gholizadeh Mesgarha M, et al (2022) A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. Dermatol Ther 35(6):e15461. https:\/\/doi.org\/10.1111\/dth.15461","journal-title":"Dermatol Ther"},{"issue":"8","key":"18_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15590","volume":"35","author":"TNA Tran","year":"2022","unstructured":"Tran TNA, Nguyen TTP, Pham NN, et al (2022) New onset of psoriasis following COVID-19 vaccination. Dermatol Ther 35(8):e15590. https:\/\/doi.org\/10.1111\/dth.15590","journal-title":"Dermatol Ther"},{"key":"18_CR13","doi-asserted-by":"publisher","unstructured":"Chhabra N, C AG (2022) A case of de novo annular-plaque type psoriasis following Oxford-AstraZeneca COVID-19 vaccination. Curr Drug Saf.. https:\/\/doi.org\/10.2174\/1574886317666220613163327","DOI":"10.2174\/1574886317666220613163327"},{"issue":"8","key":"18_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15651","volume":"35","author":"S Shakoei","year":"2022","unstructured":"Shakoei S, Kalantari Y, Nasimi M, et al (2022) Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases. Dermatol Ther 35(8):e15651. https:\/\/doi.org\/10.1111\/dth.15651","journal-title":"Dermatol Ther"},{"issue":"4","key":"18_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13695","volume":"33","author":"AMG Brunasso","year":"2020","unstructured":"Brunasso AMG, Massone C (2020) Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy. Dermatol Ther 33(4):e13495. https:\/\/doi.org\/10.1111\/dth.13695","journal-title":"Dermatol Ther"},{"issue":"8","key":"18_CR16","first-page":"815","volume":"18","author":"T Buhl","year":"2020","unstructured":"Buhl T, Beissert S, Gaffal E, et al (2020) COVID-19 and implications for dermatological and allergological diseases. J Dtsch Dermatol Ges 18(8):815\u2013824","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"18_CR17","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/ijd.15189","volume":"59","author":"K Drenovska","year":"2020","unstructured":"Drenovska K, Schmidt E, Vassileva S (2020) Covid-19 pandemic and the skin. Int J Dermatol 59(11):1312\u20131319","journal-title":"Int J Dermatol"},{"issue":"2","key":"18_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/15569527.2021.1919138","volume":"40","author":"H Molaee","year":"2021","unstructured":"Molaee H, Allahyari F, Emadi SN, et al (2021) Cutaneous manifestations related to the COVID-19 pandemic: a review article. Cutan Ocul Toxicol 40(2):168\u2013174","journal-title":"Cutan Ocul Toxicol"},{"key":"18_CR19","doi-asserted-by":"publisher","unstructured":"Krueger JG, Bowcock A (2005) Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 Suppl 2(Suppl 2):ii30-6. https:\/\/doi.org\/10.1136\/ard.2004.031120","DOI":"10.1136\/ard.2004.031120"},{"key":"18_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175147","volume":"929","author":"G Hari","year":"2022","unstructured":"Hari G, Kishore A, Karkala SRP (2022) Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached? Eur J Pharmacol 929:175147. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175147","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"18_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.5662\/wjm.v12.i4.200","volume":"12","author":"M Al-Beltagi","year":"2022","unstructured":"Al-Beltagi M, Saeed NK, Bediwy AS (2022) COVID-19 disease and autoimmune disorders: A mutual pathway. World J Methodol 12(4):200\u2013223","journal-title":"World J Methodol"},{"key":"18_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102898","volume":"132","author":"Y Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez Y, Rojas M, Beltr\u00e1n S, et al (2022) Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun 132:102898. https:\/\/doi.org\/10.1016\/j.jaut.2022.102898","journal-title":"J Autoimmun"},{"issue":"36","key":"18_CR23","doi-asserted-by":"publisher","first-page":"54072","DOI":"10.1007\/s11356-022-20984-7","volume":"29","author":"T Darmarajan","year":"2022","unstructured":"Darmarajan T, Paudel KR, Candasamy M, et al (2022) Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation. Environ Sci Pollut Res Int 29(36):54072\u201354087","journal-title":"Environ Sci Pollut Res Int"},{"key":"18_CR24","unstructured":"World Health Organization; Global Report on Psoriasis (2016). https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/204417\/9789241565189_eng.pdf.psoriasis?sequence=1. Accessed October 18, 2022"},{"key":"18_CR25","unstructured":"Mayo Clinic; Psoriasis; Treatment; Oral or Injected Medications. https:\/\/www.mayoclinic.org\/diseases-conditions\/psoriasis\/diagnosis-treatment\/drc-20355845#:~:text=Options%20include%20apremilast%20(Otezla)%2C,)%20and%20certolizumab%20(Cimzia). Accessed October 19, 2022"},{"issue":"4","key":"18_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13345","volume":"33","author":"V Di Lernia","year":"2020","unstructured":"Di Lernia V (2020) Antipsoriatic treatments during COVID-19 outbreak. Dermatol Ther 33(4):e13345. https:\/\/doi.org\/10.1111\/dth.13345","journal-title":"Dermatol Ther"},{"issue":"4","key":"18_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13360","volume":"33","author":"A Abdelmaksoud","year":"2020","unstructured":"Abdelmaksoud A, Goldust M, Vestita M (2020) Comment on \"COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action\". Dermatol Ther 33(4):e13360. https:\/\/doi.org\/10.1111\/dth.13360","journal-title":"Dermatol Ther"},{"issue":"4","key":"18_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/09546634.2020.1749545","volume":"31","author":"F Bardazzi","year":"2020","unstructured":"Bardazzi F, Loi C, Sacchelli L, Di Altobrando A (2020) Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat 31(4):320\u2013321","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"18_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/09546634.2020.1757605","volume":"31","author":"M Megna","year":"2020","unstructured":"Megna M, Ruggiero A, Marasca C, Fabbrocini G (2020) Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat 31(4):328\u2013329","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"18_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13467","volume":"33","author":"M Megna","year":"2020","unstructured":"Megna M, Napolitano M, Patruno C, Fabbrocini G (2020) Biologics for psoriasis in COVID-19 era: What do we know? Dermatol Ther 33(4):e13467. https:\/\/doi.org\/10.1111\/dth.13467","journal-title":"Dermatol Ther"},{"key":"18_CR31","doi-asserted-by":"publisher","unstructured":"Naldi L (2021) Risk of infections in psoriasis. A lesson to learn during the SARS-CoV-2 pandemic. Br J Dermatol 184(1):6. https:\/\/doi.org\/10.1111\/bjd.19190","DOI":"10.1111\/bjd.19190"},{"issue":"1","key":"18_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14691","volume":"34","author":"A Kara Polat","year":"2021","unstructured":"Kara Polat A, Oguz Topal I, Karadag AS, et al (2021) The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatol Ther 34(1):e14691. https:\/\/doi.org\/10.1111\/dth.14691","journal-title":"Dermatol Ther"},{"issue":"2","key":"18_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bjd.19158","volume":"183","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Facheris P, Dapavo P, et al (2020) The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol 183(2):373\u2013374","journal-title":"Br J Dermatol"},{"issue":"1","key":"18_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jaad.2020.04.165","volume":"83","author":"A Carugno","year":"2020","unstructured":"Carugno A, Gambini DM, Raponi F, et al (2020) COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy. J Am Acad Dermatol 83(1):292\u2013294","journal-title":"Italy. J Am Acad Dermatol"},{"issue":"5","key":"18_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13475","volume":"33","author":"G Damiani","year":"2020","unstructured":"Damiani G, Pacifico A, Bragazzi NL, Malagoli P (2020) Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther 33(5):e13475. https:\/\/doi.org\/10.1111\/dth.13475","journal-title":"Dermatol Ther"},{"issue":"8","key":"18_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237367","volume":"13","author":"K Gananandan","year":"2020","unstructured":"Gananandan K, Sacks B, Ewing I (2020) Guttate psoriasis secondary to COVID-19. BMJ Case Rep 13(8):e237367. https:\/\/doi.org\/10.1136\/bcr-2020-237367","journal-title":"BMJ Case Rep"},{"issue":"7","key":"18_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4542","volume":"9","author":"M Rouai","year":"2021","unstructured":"Rouai M, Rabhi F, Mansouri N, et al (2021) New-onset guttate psoriasis secondary to COVID-19. Clin Case Rep 9(7):e04542. https:\/\/doi.org\/10.1002\/ccr3.4542","journal-title":"Clin Case Rep"},{"issue":"1","key":"18_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/bjd.20659","volume":"186","author":"L Penso","year":"2022","unstructured":"Penso L, Dray-Spira R, Weill A, et al (2022) Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br J Dermatol 186(1):59\u201368","journal-title":"Br J Dermatol"},{"issue":"5","key":"18_CR39","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jaad.2021.07.054","volume":"85","author":"S Wack","year":"2021","unstructured":"Wack S, Patton T, Ferris LK (2021) COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol 85(5):1274\u20131284","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"18_CR40","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","volume":"80","author":"UM Geisen","year":"2021","unstructured":"Geisen UM, Berner DK, Tran F, et al (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80(10):1306\u20131311","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"18_CR41","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","volume":"80","author":"D Simon","year":"2021","unstructured":"Simon D, Tascilar K, Fagni F, et al (2021) SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis 80(10):1312\u20131316","journal-title":"Ann Rheum Dis"},{"key":"18_CR42","doi-asserted-by":"crossref","unstructured":"Skroza N, Bernardini N, Tolino E, et al (2021) Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience. J Clin Med 10(15):","DOI":"10.3390\/jcm10153355"},{"issue":"6","key":"18_CR43","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/ced.14631","volume":"46","author":"G Damiani","year":"2021","unstructured":"Damiani G, Allocco F, Malagoli P (2021) COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers. Clin Exp Dermatol 46(6):1106\u20131108","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"18_CR44","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","volume":"84","author":"JM Gelfand","year":"2021","unstructured":"Gelfand JM, Armstrong AW, Bell S, et al (2021) National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol 84(5):1254\u20131268","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"18_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/ced.14895","volume":"47","author":"S Elamin","year":"2022","unstructured":"Elamin S, Hinds F,Tolland J (2022) De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. Clin Exp Dermatol 47(1):153\u2013155","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"18_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15085","volume":"34","author":"P Nagrani","year":"2021","unstructured":"Nagrani P, Jindal R, Goyal D (2021) Onset\/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca\/Covishield): Report of two cases. Dermatol Ther 34(5):e15085. https:\/\/doi.org\/10.1111\/dth.15085","journal-title":"Dermatol Ther"},{"issue":"1","key":"18_CR47","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1111\/1346-8138.16203","volume":"49","author":"WJ Song","year":"2022","unstructured":"Song WJ, Lim Y, Jo SJ (2022) De novo guttate psoriasis following coronavirus disease 2019 vaccination. J Dermatol 49(1):e30\u2013e31","journal-title":"J Dermatol"},{"issue":"11","key":"18_CR48","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1111\/jdv.17561","volume":"35","author":"M Lehmann","year":"2021","unstructured":"Lehmann M, Schorno P, Hunger RE, et al (2021) New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol 35(11):e752\u2013e755","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"18_CR49","doi-asserted-by":"crossref","unstructured":"Ricardo JW, Lipner SR (2021) Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. JAAD Case Rep 1718\u20131720","DOI":"10.1016\/j.jdcr.2021.09.009"},{"key":"18_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/258430","volume":"2015","author":"AT Gunes","year":"2015","unstructured":"Gunes AT, Fetil E, Akarsu S, et al (2015) Possible Triggering Effect of Influenza Vaccination on Psoriasis. J Immunol Res 2015:258430. https:\/\/doi.org\/10.1155\/2015\/258430","journal-title":"J Immunol Res"},{"issue":"6","key":"18_CR51","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40257-022-00721-z","volume":"23","author":"PC Wu","year":"2022","unstructured":"Wu PC, Huang IH, Wang CW, et al (2022) New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review. Am J Clin Dermatol 23(6):775\u2013799","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"18_CR52","first-page":"e632","volume":"35","author":"PK Krajewski","year":"2021","unstructured":"Krajewski PK, Matusiak \u0141, Szepietowski JC (2021) Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol 35(10):e632\u2013e634","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"18_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15331","volume":"35","author":"I Durmaz","year":"2022","unstructured":"Durmaz I, Turkmen D, Altunisik N,Toplu SA (2022) Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID-19 vaccine: A report of three cases. Dermatol Ther 35(4):e15331. https:\/\/doi.org\/10.1111\/dth.15331","journal-title":"Dermatol Ther"},{"key":"18_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdcr.2021.08.035","volume":"17","author":"D Perna","year":"2021","unstructured":"Perna D, Jones J, Schadt CR (2021) Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep 17:1\u20133","journal-title":"JAAD Case Rep"},{"key":"18_CR55","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jdin.2021.11.004","volume":"6","author":"CZY Phuan","year":"2022","unstructured":"Phuan CZY, Choi EC-E,Oon HH (2022) Temporary exacerbation of pre-existing psoriasis and eczema in the context of COVID-19 messenger RNA booster vaccination: A case report and review of the literature. JAAD International 6:94\u201396","journal-title":"JAAD International"},{"issue":"5","key":"18_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15055","volume":"34","author":"K Mieczkowska","year":"2021","unstructured":"Mieczkowska K, Kaubisch A,McLellan BN (2021) Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor. Dermatol Ther 34(5):e15055. https:\/\/doi.org\/10.1111\/dth.15055","journal-title":"Dermatol Ther"},{"issue":"6","key":"18_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15110","volume":"34","author":"E Bostan","year":"2021","unstructured":"Bostan E, Elmas L, Yel B,Yalici-Armagan B (2021) Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases. Dermatol Ther 34(6):e15110. https:\/\/doi.org\/10.1111\/dth.15110","journal-title":"Dermatol Ther"},{"issue":"11","key":"18_CR59","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1111\/1346-8138.16137","volume":"48","author":"WC Fang","year":"2021","unstructured":"Fang WC, Chiu LW,Hu SC (2021) Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine. J Dermatol 48(11):e566\u2013e567","journal-title":"J Dermatol"},{"issue":"6","key":"18_CR60","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1111\/jdv.17965","volume":"36","author":"D Koumaki","year":"2022","unstructured":"Koumaki D, Krueger-Krasagakis SE, et al (2022) Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre. J Eur Acad Dermatol Venereol 36(6):e411\u2013e415","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"18_CR61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jdcr.2021.11.016","volume":"19","author":"N Wei","year":"2022","unstructured":"Wei N, Kresch M, Elbogen E,Lebwohl M (2022) New onset and exacerbation of psoriasis after COVID-19 vaccination. JAAD Case Reports 19:74\u201377","journal-title":"JAAD Case Reports"},{"issue":"12","key":"18_CR62","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.1111\/jdv.17582","volume":"35","author":"E Sotiriou","year":"2021","unstructured":"Sotiriou E, Tsentemeidou A, Bakirtzi K, Lallas A, Ioannides D,Vakirlis E (2021) Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol 35(12):e857\u2013e859","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"18_CR63","doi-asserted-by":"crossref","unstructured":"Megna M, Potestio L, Gallo L, Caiazzo G, Ruggiero A,Fabbrocini G (2022) Reply to \u201cPsoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre\u201d by Sotiriou E et al. Journal of the European Academy of Dermatology and Venereology 36(1):e11\u2013e13","DOI":"10.1111\/jdv.17665"},{"key":"18_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.812010","volume":"8","author":"YW Huang","year":"2021","unstructured":"Huang YW, Tsai TF (2021) Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center. Front Med (Lausanne) 8:812010. https:\/\/doi.org\/10.3389\/fmed.2021.812010","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"18_CR65","doi-asserted-by":"publisher","first-page":"261","DOI":"10.34172\/hpp.2021.32","volume":"11","author":"N Onsun","year":"2021","unstructured":"Onsun N, Kaya G, I\u015f\u0131k BG,G\u00fcne\u015f B (2021) A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report. Health Promot Perspect 11(2):261\u2013262","journal-title":"Health Promot Perspect"},{"issue":"5","key":"18_CR66","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1111\/jdv.17918","volume":"36","author":"V Piccolo","year":"2022","unstructured":"Piccolo V,Russo T,Mazzatenta C,Bassi A,Argenziano G,Cutrone M et al. (2022) COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol 36(5):e330\u2013e332","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"18_CR67","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1111\/jdv.17502","volume":"35","author":"L Quattrini","year":"2021","unstructured":"Quattrini L, Verardi L, Caldarola G, Peluso G, De Simone C,D\u2019Agostino M (2021) New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination. J Eur Acad Dermatol Venereol 35(11):e727\u2013e729","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"18_CR68","unstructured":"World Health Organization; Types of COVID-19 vaccines. https:\/\/www.who.int\/westernpacific\/emergencies\/covid-19\/covid-19-vaccines. Accessed October 2022"},{"key":"18_CR69","unstructured":"European Medicines Agency; Adapted COVID-19 vaccines. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/covid-19-vaccines-authorised. Accessed October 20, 2022"},{"issue":"2","key":"18_CR70","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000362808","volume":"229","author":"E Sbidian","year":"2014","unstructured":"Sbidian E, Eftekahri P, Viguier M, et al (2014) National survey of psoriasis flares after 2009 monovalent H1N1\/seasonal vaccines. Dermatology 229(2):130\u2013135","journal-title":"Dermatology"},{"issue":"5","key":"18_CR71","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s10067-022-06149-4","volume":"41","author":"LJ Jara","year":"2022","unstructured":"Jara LJ, Vera-Lastra O, Mahroum N, et al (2022) Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune\/inflammatory syndrome expand? Clin Rheumatol 41(5):1603\u20131609","journal-title":"Clin Rheumatol"},{"key":"18_CR73","doi-asserted-by":"publisher","unstructured":"Aryanian Z, Balighi K, Afshar ZM, et al (2022) COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic. J Cosmet Dermatol https:\/\/doi.org\/10.1111\/jocd.15448","DOI":"10.1111\/jocd.15448"},{"issue":"4","key":"18_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12945","volume":"92","author":"LL Ten Bergen","year":"2020","unstructured":"Ten Bergen LL, Petrovic A, Aarebrot AK, Appel S (2020) Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol 92(4):e12945. https:\/\/doi.org\/10.1111\/sji.12945","journal-title":"Scand J Immunol"},{"issue":"6","key":"18_CR75","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/art.40830","volume":"71","author":"Y Yuan","year":"2019","unstructured":"Yuan Y, Qiu J, Lin ZT, et al (2019) Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol 71(6):941\u2013951","journal-title":"Arthritis Rheumatol"},{"key":"18_CR76","unstructured":"POTS\/Long Covid-diagnostics; CellTrend; https:\/\/www.celltrend.de\/en\/pots-cfs-me-sfn\/. Accessed September 4, 2022"},{"key":"18_CR77","unstructured":"EUROIMMUN Autoantibodies in neurological diseases. https:\/\/www.euroimmun.com\/documents\/Indications\/Autoimmunity\/Neurology\/MAG_myelin_GAD\/FA_1111_I_UK_A.pdf. Accessed September 4, 2022"},{"key":"18_CR78","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/978-1-0716-2395-4_18","volume":"2511","author":"PC Guest","year":"2022","unstructured":"Guest PC, Abbasifard M, Jamialahmadi T, et al (2022) Multiplex Immunoassay for Prediction of Disease Severity Associated with the Cytokine Storm in COVID-19 Cases. Methods Mol Biol 2511:245\u2013256","journal-title":"Methods Mol Biol"},{"key":"18_CR79","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/978-1-0716-2395-4_21","volume":"2511","author":"F Zahedipour","year":"2022","unstructured":"Zahedipour F, Guest PC, Majeed M, et al (2022) Evaluating the Effects of Curcumin on the Cytokine Storm in COVID-19 Using a Chip-Based Multiplex Analysis. Methods Mol Biol 2511:285\u2013295","journal-title":"Methods Mol Biol"},{"key":"18_CR80","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13167-015-0046-y","volume":"6","author":"L Einhorn","year":"2015","unstructured":"Einhorn L, Krapfenbauer K (2015) HTRF: a technology tailored for biomarker determination-novel analytical detection system suitable for detection of specific autoimmune antibodies as biomarkers in nanogram level in different body fluids. EPMA J 6:23. https:\/\/doi.org\/10.1186\/s13167-015-0046-y","journal-title":"EPMA J"},{"key":"18_CR81","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-4939-6730-8_25","volume":"1546","author":"H Peter","year":"2017","unstructured":"Peter H, Wienke J, Bier FF (2017) Lab-on-a-Chip Multiplex Assays. Methods Mol Biol 1546:283\u2013294","journal-title":"Methods Mol Biol"},{"key":"18_CR82","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-0716-2395-4_17","volume":"2511","author":"H Peter","year":"2022","unstructured":"Peter H, Mattig E, Guest PC, Bier FF (2022) Lab-on-a-Chip Immunoassay for Prediction of Severe COVID-19 Disease. Methods Mol Biol 2511:235\u2013244","journal-title":"Methods Mol Biol"},{"key":"18_CR83","doi-asserted-by":"crossref","unstructured":"European Medicines Agency; Safety of COVID-19 vaccines. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/safety-covid-19-vaccines. Accessed October 20, 2022","DOI":"10.1080\/21645515.2023.2263982"},{"issue":"1","key":"18_CR84","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","volume":"85","author":"DE McMahon","year":"2021","unstructured":"McMahon DE, Amerson E, Rosenbach M, et al (2021) Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol 85(1):46\u201355","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"18_CR85","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjd.20639","volume":"186","author":"A Catal\u00e0","year":"2022","unstructured":"Catal\u00e0 A, Mu\u00f1oz-Santos C, Galv\u00e1n-Casas C, et al (2022) Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol 186(1):142\u2013152","journal-title":"Br J Dermatol"},{"issue":"9","key":"18_CR86","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1111\/jocd.15209","volume":"21","author":"F Cebeci Kahraman","year":"2022","unstructured":"Cebeci Kahraman F, Sava\u015f Erdo\u011fan S, et al (2022) Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study. J Cosmet Dermatol 21(9):3692\u20133703","journal-title":"J Cosmet Dermatol"},{"issue":"9","key":"18_CR87","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1111\/jocd.15203","volume":"21","author":"E Bostan","year":"2022","unstructured":"Bostan E, Yel B, Karaduman A (2022) Cutaneous adverse events following 771 doses of the inactivated and mRNA COVID-19 vaccines: A survey study among health care providers. J Cosmet Dermatol 21(9):3682\u20133688","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"18_CR88","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40257-022-00715-x","volume":"23","author":"JM Falotico","year":"2022","unstructured":"Falotico JM, Desai AD, Shah A, et al (2022) Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database. Am J Clin Dermatol 23(5):729\u2013737","journal-title":"Am J Clin Dermatol"}],"container-title":["Advances in Experimental Medicine and Biology","Application of Omic Techniques to Identify New Biomarkers and Drug Targets for COVID-19"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-28012-2_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T23:24:57Z","timestamp":1702682697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-28012-2_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031280115","9783031280122"],"references-count":86,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-28012-2_18","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"29 June 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}